primarily revolving around promising clinical trial results for Silence Therapeutics’ lead product candidate, zerlasiran. The recent data from the ALPACAR-360 phase II study presented at the American ...

Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile ...

Actively Exploring Partnership for Alzheimer's DevelopmentSupplementary Financing Concluded in Q4 ROCHESTER, N.Y., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage bio ...

Notes payable, plus accrued interest, totaled approximately $6.9 million. The current portion of the notes payable plus accrued interest totaled approximately $3.7 million. Included in the current ...

Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt ... Safety Monitoring Board for both our Phase 2 and Phase 3 Stargardt disease trials further validates ...

Between the Phase I and II trials for NTLA-2002, 12 of 15 patients treated with NTLA-2002 have reached a functional cure for ...

Unsupervised use of hallucinogens like LSD is high, posing significant risks. However, LSD is being clinically tested for treating anxiety and so far seems effective.

The FDA is set to decide on four promising therapies in the next two weeks, including a CAR T for acute lymphoblastic ...

A phase 1 clinical trial (NCT06343805) evaluating AJ1-11095, a first-in-class type II JAK2 inhibitor for the treatment of myelofibrosis, has enrolled its first patient. 1 “There continues to be a ...

Three phase 3 trials of combinations including datopotamab deruxtecan for the treatment of non–small cell lung cancer are beginning. The first patients have been dosed in 3 phase 3 trials evaluating ...